Why Your CJC+Ipamorelin Isn't Working on Retatrutide

Your pituitary releases growth hormone in pulses, and those pulses are gated by two signals that travel up from your bloodstream: something called GHRH, which is the "go" signal, and something called somatostatin, which is the "stop" signal. When you inject CJC-1295, you are mimicking GHRH. When you inject Ipamorelin, you are mimicking a separate "go" signal called ghrelin. Together they push the pituitary hard to release a large pulse of growth hormone.

But there is a third signal that can shut the whole system down before it even starts.

Insulin. When insulin is elevated, it binds to receptors on the somatotroph cells in your pituitary, the exact cells that produce and release growth hormone, and suppresses their output. The growth hormone pulse you paid for just does not happen. This is why the standard rule for every growth hormone secretagogue, whether CJC and Ipamorelin, Tesamorelin, or Sermorelin, has always been to inject fasted, typically two hours after your last meal. Enough time for your insulin to come back down to baseline.

That rule was built for people with normal digestion.

When you add Retatrutide to the stack, normal digestion no longer applies. Retatrutide carries GLP-1 receptor agonist activity, and one of the primary jobs of GLP-1 signaling is to slow something called gastric emptying, which is just the rate at which food moves from your stomach into your small intestine, where it actually gets absorbed. Slower gastric emptying means nutrients trickle into your bloodstream over a longer window, which means insulin stays elevated for longer than it would otherwise.

Researchers measured exactly how much longer. In a study on semaglutide, another GLP-1 receptor agonist with a similar mechanism, gastric half-emptying time, meaning the time for 50 percent of a meal to leave the stomach, increased from 118 minutes on placebo to 171 minutes on the drug. That is more than 50 minutes longer. At the two-hour mark specifically, there was 25.5 percent more food still sitting in the stomach compared to people not on the drug. And at three hours, that gap had grown to 38 percent more retained, not shrunk. The delay compounds over time rather than catching up.

Separate research from an anesthesiology context found that patients on GLP-1 receptor agonists who fasted for anywhere from seven to eighteen hours still had solid gastric contents present. That data point is what pushed anesthesiologists to revise their pre-operative fasting guidelines for patients on these drugs, because the standard eight-hour fast that had been considered reliable for decades could no longer be trusted.

Retatrutide specifically was tested as well. Researchers found that at doses of 3mg and above, it delayed the peak absorption of acetaminophen, which is a standard proxy marker for how quickly the stomach is emptying, by approximately one hour. And that effect was still present at day 30 and day 79 of dosing, meaning the delay does not attenuate as your body adapts. It persists at steady state.

Now bring that back to the practical situation. You eat dinner at seven. You inject CJC and Ipamorelin at nine because you have followed the two-hour rule. On a normal digestive timeline, that would be appropriate. Food is largely through the stomach, insulin is trending back down. But on Retatrutide, a meaningful portion of that meal is still sitting in your stomach at nine. Absorption is still happening. Insulin is still elevated. And when you inject, the growth hormone pulse you are trying to drive gets suppressed at the source before it can even clear the pituitary.

You are running two competing signals at once. The peptides are pressing the gas, and the insulin is pressing the brake, and the brake wins at the pituitary level.

The two-hour rule was never arbitrary. It was calibrated to normal gastric emptying physiology. When you change the gastric emptying physiology with a GLP-1 drug, the rule has to change with it.

The most practical solution is to move growth hormone peptides to the morning, and specifically to the first injection of the day after overnight sleep. Eight to ten hours of sleep without food intake is a fasting window that even significantly delayed gastric emptying cannot undermine. By the time you wake up, there is nothing left in the stomach to absorb regardless of how slow the drug has made your digestion, and your insulin is at its true overnight baseline.

One concern people raise about morning dosing is whether it is as effective as evening dosing for building IGF-1, the downstream anabolic signal that growth hormone drives when it reaches the liver. The data here is reassuring. A study comparing evening versus morning growth hormone injections in GH-deficient patients found that 24-hour IGF-1 levels were equivalent between the two timing strategies. The liver does not particularly care what time of day it receives the growth hormone signal, only that insulin is present in sufficient amounts when that signal arrives, because insulin is what allows the liver to convert growth hormone into IGF-1.

This means the practical sequence for morning dosing looks like this: inject fasted upon waking, wait 30 to 60 minutes for the growth hormone pulse to develop, then eat your first meal, which will naturally raise insulin and give the liver what it needs to generate IGF-1.

The broader point is that every compound you add to a stack changes the physiological environment that every other compound is operating in. Retatrutide does not just affect appetite and body weight. It changes your insulin response curve, your gastric transit time, and the effective fasting window available to you. If you are dosing based on rules built for a different physiological state, you are not actually running the stack you think you are running.

That is the whole problem. And shifting your injection window by a few hours fixes it entirely.

---

References

1. Urva S, Coskun T, Loghin C, et al. 2023. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity and Metabolism. Finding: Retatrutide at doses ≥3mg delayed acetaminophen Tmax by approximately 1 hour, with effects persisting at Day 30 and Day 79. Source
2. Jensterle M, et al. 2023. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, Obesity and Metabolism. Finding: Gastric half-emptying time increased from 118 minutes to 171 minutes on semaglutide. At 2 hours, 25.5% more gastric contents retained vs placebo. At 3 hours, 38% more retained. Source
3. Silveira SQ, et al. 2023. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. Journal of Clinical Endocrinology \& Metabolism. Finding: GLP-1 RA patients had gastric half-emptying of 138 minutes vs 95 minutes on placebo. Patients fasting 7-18 hours still had retained solid gastric contents. Source
4. Jorgensen JO, et al. 1990. Evening versus morning injections of growth hormone in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab. Finding: 24-hour IGF-1 levels were equivalent between morning and evening injection timing. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness